Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 6:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 60 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Nexium Clear all

Conditions: Healthy
Interventions: Esomeprazole Magnesium; Drug
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Duarte, California

Conditions: Chronic Pancreatitis
Interventions: Nexium (esomeprazole magnesium), Placebo to Nexium, Viokase 16 (pancrelipase) + Nexium, Viokase 16 + placebo to Nexium; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 75 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Barrett Esophagus, Esophageal Cancer
Interventions: acetylsalicylic acid, esomeprazole magnesium, placebo; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Heartburn
Interventions: Esomeprazole; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 340 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 10
States / cities: Sacramento, California • Seminole, Florida • Meridian, Idaho + 7 more

Conditions: Juvenile Idiopathic Arthritis (JIA)
Interventions: VIMOVO 250/20, VIMOVO 375/20, VIMOVO 500/20; Drug
Lead sponsor: Amgen; Industry
Eligibility: 12 Years to 16 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 17
States / cities: Little Rock, Arkansas • San Francisco, California • Aurora, Colorado + 14 more

Conditions: Exercise Triggered Asthma, Gastroesophageal Reflux
Interventions: Nexium, Placebo; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Healthy Participants
Interventions: BMS-986278 Tablet, Esomeprazole, BMS-986278 suspension; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 21 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Pharmacokinetics of Isavuconazole, Healthy Subjects
Interventions: Isavuconazole, Esomeprazole; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy Volunteers
Interventions: TAK-906, Esomeprazole; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Esophagitis
Interventions: esomeprazole, fluticasone; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Gastroesophageal Reflux
Interventions: Nexium, Sugar Pill; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Dyspepsia
Interventions: Esomeprazole Magnesium; Drug
Lead sponsor: Medstar Health Research Institute; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Cough, GERD
Interventions: Esomeprazole, Placebo; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 70 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Gastric Ulcer
Interventions: Esomeprazole Sodium; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 5
States / cities: Newark, Delaware • Shreveport, Louisiana • Hershey, Pennsylvania + 2 more

Conditions: Healthy
Interventions: E3810, Aciphex (rabeprazole), Nexium (esomeprazole); Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Healthy
Interventions: Nexium, Prevacid; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 2
States / cities: Los Angeles, California • Oklahoma City, Oklahoma

Conditions: Heartburn
Interventions: Esomeprazole 20 mg, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 22 Years to 65 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 2
States / cities: Oklahoma City, Oklahoma

Conditions: Dyspepsia
Interventions: dexloxiglumide, Nexium (esomeprazole); Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Eosinophilic Esophagitis, Gastroesophageal Reflux Disease, EE, GERD
Interventions: Esomeprazole, Budesonide; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 80 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Cancer
Interventions: Oral Taxane; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Timeline: Started 2006
U.S. locations: 3
States / cities: Newark, Delaware • Louisville, Kentucky • Las Vegas, Nevada

Conditions: Arthritis
Interventions: PN 400, EC naproxen plus EC esomeprazole, EC naproxen, EC esomeprazole; Drug
Lead sponsor: POZEN; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Healthy Participants
Interventions: Esomeprazole Capsule, Esomeprazole Tablet; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Erosive Esophagitis
Interventions: Nexium 20mg, Nexium 10mg; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 1 Year to 11 Years
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 11
States / cities: Mobile, Alabama • Sacramento, California • Miami, Florida + 7 more

Conditions: Gastric Ulcer
Interventions: PN400 (VIMOVO), PN 400 (VIMOVO); Drug
Lead sponsor: POZEN; Industry
Eligibility: 18 Years and older
Enrollment: 239 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Search by objective public record fields.

Plasm Gastrin Concentrations in Response to Nexium Administration in Healthy Volunteers

Viokase 16, Viokase16 Plus Nexium and Nexium Alone

Esomeprazole Magnesium With or Without Aspirin in Preventing Esophageal Cancer in Patients With Barrett Esophagus

Efficacy of Esomeprazole in Patients With Frequent Heartburn

A Safety Study of VIMOVO in Adolescents With Juvenile Idiopathic Arthritis (JIA)

Effect of Acid Reflux on Respiratory Physiology During Exercise in Athletes With GER-Response to Acid Suppression

A Study to Assess the Levels in Blood Plasma of BMS-986278 in Healthy Participants Following Administration of Tablets, With or Without Food, and in the Presence of an Antacid (Esomeprazole)

A Study to Evaluate the Effect of Multiple Doses of Esomeprazole on the Pharmacokinetics of Isavuconazole

A Trial to Evaluate the Effect of the Proton Pump Inhibitor Esomeprazole on the Single-dose Pharmacokinetics (PK) of Oral TAK-906 in Healthy Adult Participants

Comparison of Esomeprazole to Aerosolized, Swallowed Fluticasone for Eosinophilic Esophagitis

Which Supraesophageal Reflux Symptoms Reliably Respond to Proton-Pump-Inhibitor (PPI) Therapy

Total Antioxidant Effects of Esomeprazole in Dyspeptic Patients Receiving Non-steroidal Anti-inflammatory Drugs

The Utility of Nexium in Chronic Cough and Reflux Disease

An Open-label, Exploratory Trial to Assess Gastric Acid Control in Critically Ill Subjects Receiving Nexium

A Study to Evaluate the Effect on 24-hour, Intragastric pH of RAB ER 50-mg Capsules Compared With Esomeprazole (Nexium) 40 mg Capsules and Rabeprazole (Aciphex) 20-mg Tablets

Study of 24-hour Intragastric pH Profiles of Esomeprazole 40 mg and Lansoprazole 30 mg in Healthy Volunteer Subjects

Pilot Study To Investigate The Association Between Acid Control And Heartburn Symptoms After Proton Pump Inhibitor Treatment

The Safety and Efficacy of Dexloxiglumide for the Relief of Symptoms of Functional Dyspepsia.

The Role Of Gastroesophageal Reflux Disease (GERD) in Eosinophilic Esophagitis

A Phase I Study of BMS-275183 (Oral Taxane) Given on a Daily Schedule in Combination With Esomeprazole (Nexium) in Patients With Advanced Cancer

A Pharmacokinetic (PK) Study Evaluating Naproxen and Esomeprazole Plasma Levels

A Study to Evaluate the Bioequivalence of Single Oral Dose of Esomeprazole Capsule and Tablet Formulation in Healthy Participants

Endoscopic Evidence of Maintenance of Healing With Oral NEXIUM in Patients 1 to 11 Years Old With Erosive Esophagitis.

A 12-month, Phase 3, Open-label, Multi-center Study to Evaluate the Long-term Safety of PN400 (VIMOVO)